Symbolbild · KI-generiert
MoonLake Immunotherapeutics
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company specialising in Nanobody-based therapies for inflammatory diseases. Its lead candidate Sonelokimab is a trispecific Nanobody that inhibits IL-17A and IL-17F and is being investigated in studies covering psoriatic arthritis, hidradenitis suppurativa and plaque psoriasis. The company is headquartered in Switzerland.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| MoonLake Immunotherapeutics | MLTX | NASDAQ | 1,36 Mrd. USD |
| Kestra Medical Technologies, Ltd. | KMTS | NASDAQ | 1,34 Mrd. USD |
| Tandem Diabetes Care, Inc. | TNDM | NASDAQ | 1,34 Mrd. USD |
| CONMED Corporation | CNMD | NYSE | 1,39 Mrd. USD |
| ArriVent BioPharma, Inc. | AVBP | NASDAQ | 1,39 Mrd. USD |
| Personalis, Inc. | PSNL | NASDAQ | 1,33 Mrd. USD |
| Xeris Biopharma Holdings, Inc. | XERS | NASDAQ | 1,39 Mrd. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.